2 ballot items.
Two proposals are being voted on at Century Therapeutics' 2026 Special Meeting: a discretionary reverse stock split to 1-for-5 to 1-for-30 with Board discretion, and an adjournment to seek additional votes.
Authorize the Board to effect a reverse stock split in the range 1-for-5 to 1-for-30, at its discretion, which would adjust the number of shares outstanding and potentially impact equity awards, with the aim of regaining Nasdaq listing compliance and improving marketability and investor perception.
Authorize adjourning the Special Meeting to permit solicitation of additional proxies if there are insufficient votes to approve Proposal 1 or to establish a quorum.
| # | Owner | % of shares | Shares | Value |
|---|---|---|---|---|
| 1 | RA CAPITAL MANAGEMENT, L.P. | 9.84% | 17,754,430 | $40M |
| 2 | TCG Crossover Management, LLC | 9.84% | 17,754,430 | $39M |
| 3 | Versant Venture Management, LLC | 6.75% | 12,166,109 | $27M |
| 4 | Deep Track Capital, LP | 5.26% | 9,487,745 | $21M |
| 5 | RTW INVESTMENTS, LP | 4.82% | 8,695,652 | $20M |
| 6 | Commodore Capital LP | 4.82% | 8,695,652 | $20M |
| 7 | Venrock Adviser, LLC | 4.82% | 8,695,652 | $20M |
| 8 | Point72 Asset Management, L.P.Activist | 3.31% | 5,964,678 | $13M |
| 9 | VANGUARD CAPITAL MANAGEMENT LLC | 3.15% | 5,686,204 | $13M |
| 10 | BALYASNY ASSET MANAGEMENT L.P. | 2.78% | 5,017,733 | $11M |
The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.
This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.
None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.
No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.
